• Explore /
  • Poster
  • / Phase 1b/2 trial of pepinemab plus avelumab as second line combination immunotherapy for patients with metastatic pancreatic adenocarcinoma.

Phase 1b/2 trial of pepinemab plus avelumab as second line combination immunotherapy for patients with metastatic pancreatic adenocarcinoma.

Abstract Video & Slides Poster

Authors

null

Luis I. Ruffolo

University of Rochester Cancer Center & Wilmot Cancer Institute, Rochester, NY

Luis I. Ruffolo , Terrence Lee Fisher , Elizabeth E. Evans , Crystal L. Mallow , Megan Boise , Amber Foster , John E. Leonard , Brian A. Belt , Jen Jen Yeh , Maurice Zauderer , David Linehan , Daniel Mulkerin

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Pancreatic Cancer - Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT05102721

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS4195)

DOI

10.1200/JCO.2023.41.16_suppl.TPS4195

Abstract #

TPS4195

Poster Bd #

504a

Abstract Disclosures

Funded by Conquer Cancer

Similar Posters

First Author: Mark H. O'Hara

First Author: Igor Tsaur

First Author: Benjamin Adam Weinberg

First Author: Michael Seth Weinfeld